Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1Phase 2 1

Status

Unknown 20Completed 7Recruiting 5Active not recruiting 3Not yet recruiting 1

Sponsor Class

INDUSTRY 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Head & Neck 3

Conditions

Carcinoma, Non-Small-Cell Lung 33Breast Neoplasms 21Prostatic Neoplasms 17Stomach Neoplasms 10Squamous Cell Carcinoma of Head and Neck 10Lung Neoplasms 9Neoplasms 7Neoplasm Metastasis 6Carcinoma, Transitional Cell 5Triple Negative Breast Neoplasms 4Uterine Cervical Neoplasms 3Urinary Bladder Neoplasms 3Small Cell Lung Carcinoma 3Salivary Gland Neoplasms 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Pancreatic Neoplasms 3Ovarian Neoplasms 3Nasopharyngeal Carcinoma 3Melanoma 3Head and Neck Neoplasms 3Esophageal Neoplasms 3Colorectal Neoplasms 3Carcinoma 3Recurrence 2Osteosarcoma 2Non-Muscle Invasive Bladder Neoplasms 2Lymphoid Interstitial Pneumonia 2Laryngeal Neoplasms 2HER2-positive Breast Cancer 2Fallopian Tube Neoplasms 2

Interventions

Cisplatin 11Gemcitabine 10Capecitabine 6Radiotherapy, Intensity-Modulated 5Docetaxel 3toripalimab 2spartalizumab 2nimotuzumab 2fludarabine 2atezolizumab 2Specimen Handling 2Platinum 2Paclitaxel 2Magnetic Resonance Spectroscopy 2Immunoglobulin G 2Fluorouracil 2Drug Therapy 2Disulfides 2Cyclophosphamide 2Carboplatin 2Bevacizumab 21,2-diaminocyclohexaneplatinum II citrate 2tislelizumab 1sintilimab 1penpulimab 1pembrolizumab 1fludarabine phosphate 1dehydroftorafur 1camrelizumab 1X-Rays 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × Nasopharyngeal Carcinoma × Docetaxel × Clear all
NCT05063552 2026-05-13

Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
430 enrolled
Head & Neck

Lymphoid Interstitial Pneumonia, Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT06118333 2026-04-17

A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma(PANKU-NPC01)

Sichuan Baili Pharmaceutical Co., Ltd.

Phase 3 Active not recruiting
386 enrolled
Head & Neck

Nasopharyngeal Carcinoma

NCT05126719 2026-02-06

A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma

Shanghai Miracogen Inc.

Phase 2 Active not recruiting
238 enrolled
Head & Neck

Nasopharyngeal Carcinoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡